• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Alk­er­mes touts equal ef­fi­ca­cy of month­ly Viv­it­rol against dai­ly Sub­ox­one

8 years ago
Pharma

Genen­tech inks $650M deal with pro­tein degra­da­tion pi­o­neer Arv­inas

8 years ago
R&D
Pharma

Fa­tal sep­sis at­tacks blight Acor­da’s PhI­II, trig­ger­ing new safe­ty mea­sures and tor­pe­do­ing shares

8 years ago
R&D

$49M round; ex­pe­ri­enced team; A-list VCs — In­ozyme launch­es with rare dis­ease strat­e­gy and a yen for big­ger things ...

8 years ago
Financing
Startups

As­traZeneca’s res­pi­ra­to­ry group scores FDA OK for a block­buster se­vere asth­ma drug

8 years ago
Pharma

Sang­amo claims a ma­jor mile­stone in gene edit­ing, treat­ing first pa­tient with its zinc fin­ger nu­cle­ase tech

8 years ago
R&D

Award-win­ning sep­sis project gets $13M and a shot at re­open­ing an R&D av­enue as FDA pitch­es out old gold stan­dard

8 years ago
People
Financing

Mi­rati bails on lead drug, shifts fo­cus to I/O pro­gram

8 years ago
Pharma

San Diego’s stealthy Odonate sur­faces with $173M IPO

8 years ago
Financing

Im­mu­sanT scores a $40M round for PhII celi­ac study, with biotech vet Tom Daniel join­ing the board

8 years ago
People
Financing

Bay­er steps up with $1.55B deal to take a lead role in com­mer­cial­iz­ing Loxo’s can­cer drugs

8 years ago
Pharma

Torque takes tu­mor tech out of stealth with $25M back­ing, new CEO

8 years ago
Financing
Startups

Park­er In­sti­tute, MD An­der­son and Seres de­vel­op­ing a mi­cro­bio­me/PD-1/L1 com­bo; CRISPR-Cas an­timi­cro­bial biotech Lo­cus ...

8 years ago
News Briefing

Pfiz­er CEO Read hands off drug de­vel­op­ment re­spon­si­bil­i­ties to his hand picked suc­ces­sor

8 years ago
People
R&D

Neu­rode­gen­er­a­tion up­start De­nali out­lines $100M IPO for its grow­ing clin­i­cal work

8 years ago
Financing

Google backs I/O start­up Ar­cus in $107M deal

8 years ago
Financing
Startups

Prep­ping a case for canakinum­ab, No­var­tis tries to stake out a high-val­ue seg­ment of huge car­dio mar­ket

8 years ago
R&D
Pharma

Ex-Eli Lil­ly ex­ec Azar lands HHS nom­i­na­tion as Trump cham­pi­ons low­er drug prices

8 years ago
People
Pharma

Al­ny­lam's patisir­an grabs EMA ac­cel­er­at­ed re­view; CRISPR Ther­a­peu­tics, Case­bia en­ter mR­NA deal with Cure­Vac

8 years ago
News Briefing

No­var­tis spot­lights its top 4 block­buster late-stage pipeline projects

8 years ago
R&D

No­var­tis co-opts Ho­mol­o­gy's gene-edit­ing tech for R&D pipeline

8 years ago
R&D

Bill Gates has a $100M and a 5-point strat­e­gy to end 15 years of fail­ure in Alzheimer’s R&D

8 years ago
Financing
R&D

Nek­tar takes the spot­light at SITC tout­ing some promis­ing ear­ly da­ta for hard-to-treat can­cers

8 years ago
R&D

Juno us­es lethal neu­ro­tox lessons to guide Goldilocks for­mu­la for its next-gen CAR-T

8 years ago
R&D
First page Previous page 1069107010711072107310741075 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.